Novo Nordisk: Is there life after slow death for slimmed down drug maker?

Novo Nordisk has experienced a significant 52% year-to-date stock decline, with its second-quarter results confirming substantial margin pressure from heightened competition, notably Eli Lilly's Mounjaro and compounded GLP-1 alternatives, impacting Wegovy and Ozempic sales. Despite these severe competitive headwinds, Goldman Sachs suggests the associated risks are largely factored into the current share price, trading around DKK 298.30. Goldman's analysis presents a bearish scenario with potential further downside to DKK 250, but also a bullish case projecting a 35-50% upside to DKK 425-480 if Novo Nordisk successfully stabilizes pricing and defends its market share.

Analysis

Novo Nordisk's stock is under significant pressure, having declined 52% year-to-date following a recent profit warning and second-quarter results that confirmed margin erosion. The primary driver of this downturn is intensifying competition in the weight-loss drug market, specifically from Eli Lilly’s Mounjaro and lower-cost compounded GLP-1 alternatives in the US, which are squeezing sales of Wegovy and Ozempic. Despite these clear headwinds, analysis from Goldman Sachs suggests the market's reaction may be overdone, with the current share price of DKK 298.30 having already factored in these competitive risks. Goldman Sachs presents a stark bull/bear scenario analysis: a bearish outcome, where Novo Nordisk fails to defend its market and pricing power, could see the stock fall a further 20% to DKK 250 per share. Conversely, a bullish scenario, in which the company successfully stabilizes its market position and executes on its pipeline, projects a potential upside of 35% to 50%, with a fair value between DKK 425 and DKK 480 per share.

Key Decisions for Investors

• Given the significant 52% stock decline and the view that risks are priced in, investors with a high risk tolerance might consider the current valuation a compelling entry point, contingent on Novo Nordisk's ability to defend its market share.
• Investors should closely monitor competitive dynamics, particularly pricing data for Wegovy and Ozempic and market share figures relative to Eli Lilly, as these will be the lead indicators for either the bull or bear case materializing.
• The investment thesis is now heavily skewed towards a binary outcome based on execution against competition, so any long position should be weighed against the quantified downside risk of a fall to DKK 250 if the company's competitive standing deteriorates further.